Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Pontevedra (25)

2024

  1. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  2. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  3. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis

    Nefrologia

2023

  1. Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 910-915

  2. Cranial and extracranial large-vessel giant cell arteritis share a genetic pattern of interferon-gamma pathway

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 864-869

  3. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  2. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  3. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  4. Treat-To-Target in rheumatoid arthritis: A real-world study of the application and impact of treat-To-Target within the wider context of patient management, patient centricity and advanced therapy use in Europe

    RMD Open, Vol. 8, Núm. 2

  5. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2021

  1. A family-based study to identify genetic biomarkers of fibromyalgia: consideration of patients' subgroups

    Clinical and experimental rheumatology, Vol. 39, Núm. 3, pp. 144-152

  2. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  3. Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

    Aging Clinical and Experimental Research, Vol. 33, Núm. 11, pp. 2929-2939

  4. The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis

    Clinical and experimental rheumatology, Vol. 39, Núm. 2, pp. 21-26

  5. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

2020

  1. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

2019

  1. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135

2018

  1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27

  2. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96